Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Margrit Wiesendanger, MD, PhD, highlights how social determinants of health and equitable treatment access are critical to improving lupus outcomes, particularly in minority populations.

Dr Zenator Agyemang Rawlings, the Member of Parliament (MP) for Korle Klottey, has expressed commitment to leading a ...

Inspired by her own mother's battle, Dr. Lauren Powell is on a mission to improve care for lupus patients of all backgrounds.

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...

Lupus Awareness Month shines a spotlight on a disease that affects millions worldwide yet remains widely misunderstood. Lupus ...

This mysterious autoimmune disease presents with over 100 different symptoms, making diagnosis incredibly challenging for ...

A non-profit that supports lupus patients across the state is now asking Michiganders for some financial help. Members of the Michigan Lupus Foundation say they’re dealing ...

One woman learned about the extra challenges of having the autoimmune disease lupus while expecting her first child.

Kyleigh MacGregor plans her life five years at a time. MacGregor has lupus, an incurable disease in which her immune system ...